Identification of pathologically insignificant prostate cancer is not accurate in unscreened men

British Journal of Cancer

Volumn 110, Issue 10, 2014, Pages 2405-2411

  Shaw, G L ^a,b   Thomas, B C ^b   Dawson, S N ^a   Srivastava, G ^b   Vowler, S L ^a   Gnanapragasam, V J ^b   Shah, N C ^b   Warren, A Y ^b   Neal, D E ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER PATIENT; CANCER SCREENING; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AREA UNDER CURVE; BIOPSY, NEEDLE; EARLY DETECTION OF CANCER; FALSE NEGATIVE REACTIONS; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ORGAN SIZE; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SEMINAL VESICLES; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN; WATCHFUL WAITING;

EID: 84900523198     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.192     Document Type: Article

References (29)

1. pag 2405-2411 Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, Vickers A, Guillonneau B, Scardino PT, Eastham JA (2011) Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression du ring active surveillance for low risk prostate cancer. J Urol 185: 477-482.
2. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095-2101.
3. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O?Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CDPLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360: 1310-1319.
4. Ayres BE, Montgomery BS, Barber NJ, Pereira N, Langley SE, Denham P, Bott SR (2012) The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance. BJU Int 109: 1170-1176.
5. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spå ngberg A, Palmgren J, Steineck G, Adami HO, Johansson JE. SPCG-4 Investigators (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364: 1708-1717.
6. Cart er HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL (2013) Early detection of prostate cancer: AUA Guideline. J Urol 190: 419-426.
7. D?Amico AV, Whittington R,Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical pro statectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974.
8. DeLong ER DeLong DM Clarke-Pearson DL 1988 Comparing the area s under two or more correlated receiver operating characteristic curves: A nonparametric approach Biometrics 44 837-845.
9. Draisma G, Boer R, Otto SJ, Van Der Cruijsen IW, Damhuis RA, Schroder FH, De Koning HJ (2003) Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868-878.
10. Graham J, Baker M, Macbeth F, Titshall V (2008) Diagnosis and treatment of prostate cancer: Summary of NICE guidance. BMJ 336: 610-612.
11. Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Solo way MS (2012) Pathologic prostate cancer characteristics in patients eligible for active surveillance: A head-to-head comparison of contemporary protocols. Eur Urol 62: 462-468.
12. Kim TH, Jeon HG, Choo SH, Je ong BC, Seo SI, Jeon SS, Choi HY, Lee HM (2013) Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols. Int J Urol; e-pub ahead of print 29 October 2013; doi:10.1111/iju.12326.
13. Klotz L (2013) Strengthening evidence for active surveillance for prostate cancer. Eur Urol 63: 108-110.
14. MacMahon PJ, Kennedy AM, Murphy DT, Maher M, McNicholas MM (2009) Modified prostate volume algorithm improves transrectal US volume estimation in men presenting for prostate brachytherapy. Radiology 250: 273-280.
15. Melia J, Moss S, Johns L (2004) Rates of pr ostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: A cross-sectional study. BJU Int 94: 51-56.
16. Moyer VA (2012) Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157: 120-134.
17. Ochiai A, Troncoso P, Chen ME, Lloreta J, Babaian RJ (2005) The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: Implication for expectant management. J Urol 174: 2164-2168, discussion 2168.
18. Parker C, M uston D, Melia J, Moss S, Dearnaley D (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94: 1361-1368.
19. Royal Coll ege of Pathologists (2009) Dataset for histopathology reports for prostatic carcinoma. Standards and Datasets for Reporting Cancers, 2nd edn, p 29. The Royal College of Pathologists: London.
20. Selvadurai ED, Singhera M, Thomas K, Mohammed K, Woode-Amissah R, Horwich A, Huddart RA, Dearnaley DP, Parker CC (2013) Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 64: 981-987.
21. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M (2010) Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 5 8: 831-835.
22. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate canc er. Cancer 71: 933-938.
23. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB (2011) Active surveillance program for prostate cancer: An update of the Johns Hopk ins experience. J Clin Oncol 29: 2185-2190.
24. Van Den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schroder FH (2009) Outcomes of men with s creen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55: 1-8.
25. Van Der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B (2011) International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostat e cancer volume. Mod Pathol 24: 16-25.
26. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship betwe en prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol (2011) 185(5): 1656-1660.
27. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T. Prostate Cancer Inter vention versus Observation Trial (PIVOT) Study Group (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367: 203-213.
28. Wolters T, Roobol MJ, Van Leeuwen PJ, Van Den Bergh R C, Hoedemaeker RF, Van Leenders GJ, Schroder FH, Van Der Kwast TH (2011) A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 185: 121-125.
29. Xia J Gulati R Au M Gore JL Lin DW Etzioni R 2013 Effects of screening on radical prostatectomy efficacy: The prostate cancer intervention versus observation trial J Natl Cancer Inst 105 546-550